Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | Treatment of bulky stage I/II lymphoma

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the treatment of bulky stage I/II lymphoma, including strategies to reduce the risk of side effects of combined modality treatments involving radiotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

IVAC +/- rituximab in R/R B-NHLs: a real-world data review 6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial 8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
R/R lymphoma: checkpoint blockade and transplantation 2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
Latest updates in lymphoma trials 2:19
Latest updates in lymphoma trials
David Straus • 18 Aug 2020

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals